NYSEAMERICAN:BTX - BioTime Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioTime, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.13 -0.16 (-12.40 %) (As of 02/28/2020 06:00 AM ET) Add Compare Today's Range$1.05Now: $1.13▼$1.2850-Day Range N/A52-Week Range$0.66Now: $1.13▼$2.81Volume1.41 million shsAverage Volume719,479 shsMarket Capitalization$169.10 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. Read More… Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryBiotechnology SectorMedical Current SymbolNYSEAMERICAN:BTX Previous SymbolNYSEMKT:BTX CUSIP09066L10 CIK876343 Webhttp://www.biotimeinc.com/ Phone+1-510-5213390Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees76 Outstanding Shares149,643,000Market Cap$169.10 million Next Earnings DateN/A OptionableOptionable Receive BTX News and Ratings via Email Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter. AMEX:BTX Rates by TradingView BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions What is BioTime's stock symbol? BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX." How were BioTime's earnings last quarter? BioTime, Inc. (NYSEAMERICAN:BTX) released its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.06. The biotechnology company earned $1.27 million during the quarter, compared to analysts' expectations of $1.75 million. View BioTime's Earnings History. What price target have analysts set for BTX? 2 equities research analysts have issued twelve-month target prices for BioTime's stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate BioTime's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 298.2% from the stock's current price. View Analyst Price Targets for BioTime. What is the consensus analysts' recommendation for BioTime? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime. What are Wall Street analysts saying about BioTime stock? Here are some recent quotes from research analysts about BioTime stock: 1. According to Zacks Investment Research, "BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime's research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. " (8/9/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities for OpRegen (approximately 57% valuation contribution) on only the U.S. opportunity and Renevia (43% valuation contribution) in the E.U. We note that our current projected values for both these assets are based on minimal market penetration in very large markets." (8/9/2019) Has BioTime been receiving favorable news coverage? News stories about BTX stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioTime earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for BioTime. Who are some of BioTime's key competitors? Some companies that are related to BioTime include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of BioTime own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioTime investors own include Geron (GERN), Asterias Biotherapeutics (AST), CA (CA), Micron Technology (MU), Endologix (ELGX), Opko Health (OPK), BlackRock (BLK), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP) and OncoCyte (OCX). Who are BioTime's key executives? BioTime's management team includes the folowing people: Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)Mr. Brian M. Culley, CEO, Pres & Director (Age 48)Ms. Brandi L. Roberts, CFO & Sec. (Age 45)Ioana C. Hone, Director of Investor Relations How do I buy shares of BioTime? Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is BioTime's stock price today? One share of BTX stock can currently be purchased for approximately $1.13. How big of a company is BioTime? BioTime has a market capitalization of $169.10 million. BioTime employs 76 workers across the globe.View Additional Information About BioTime. What is BioTime's official website? The official website for BioTime is http://www.biotimeinc.com/. How can I contact BioTime? BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390. MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 203 (Vote Outperform)Underperform Votes: 193 (Vote Underperform)Total Votes: 396MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What is the FTSE 100 index?
